(MedPage Today) — Many patients may have to switch obesity drugs now that CVS Caremark opted to stop offering tirzepatide (Zepbound) in favor of semaglutide (Wegovy), despite the latter yielding less weight loss. (New York Times)
Transmasculine…
Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/115566
Author :
Publish date : 2025-05-13 18:08:00
Copyright for syndicated content belongs to the linked Source.
